Devic’s syndrome is also known as neuromyelitis optica which is a central nervous system disorder that specifically affects eye nerves and spinal cord.
This report contains market size and forecasts of Devic’s Syndrome (Neuromyelitis Optica) Treatment in Global, including the following market information:
Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Devic’s Syndrome (Neuromyelitis Optica) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Eculizumab Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Devic’s Syndrome (Neuromyelitis Optica) Treatment include Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), Lupin Ltd., Sagent Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., Sandoz Inc. (Novartis) and Alkem Laboratories Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Devic’s Syndrome (Neuromyelitis Optica) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Segment Percentages, by Type, 2021 (%)
Eculizumab
Methylprednisolone
Azathioprine
Mycophenolate Mofetil
Rituximab
Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinic
Others
Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Devic’s Syndrome (Neuromyelitis Optica) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Devic’s Syndrome (Neuromyelitis Optica) Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Alexion Pharmaceuticals, Inc.
Teva Pharmaceuticals
Fresenius Kabi AG
Pharmacia & Upjohn (a subsidary of Pfizer)
Lupin Ltd.
Sagent Pharmaceuticals, Inc.
Zydus Pharmaceuticals, Inc.
Sandoz Inc. (Novartis)
Alkem Laboratories Ltd.
Mylan Pharmaceuticals, Inc.
Hoffmann-La Roche/ Chugai Pharmaceutical
MedImmune LLC
RemeGen, Ltd.